These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9175302)

  • 1. Spontaneous remission in acute myelogenous leukemia: a case report.
    Gau JP; Young JH; Lin TH; Yang Y; Ho KC
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Feb; 59(2):121-5. PubMed ID: 9175302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete remission following donor PBSC after low-dose cytarabine chemotherapy for early relapse of acute myelogenous leukemia after allogeneic stem cell transplantation.
    Trenschel R; Bernier M; Stryckmans P; Verhest A; Badjou R; Crombez P; Bron D
    Bone Marrow Transplant; 1997 Feb; 19(4):381-3. PubMed ID: 9051249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant hairy cell and acute myeloid leukemia.
    Rimner T; Went P; Tichelli A; Gratwohl A
    Eur J Haematol; 2006 Jan; 76(1):86-8. PubMed ID: 16343277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
    Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Continuation of complete remission by oral administration of cytarabine ocfosfate in a patient with M0, who achieved remission by small doses of cytosine arabinoside with G-CSF].
    Aoki S; Koyama S; Goto T; Takahashi H; Shibata A
    Rinsho Ketsueki; 1995 Jan; 36(1):40-4. PubMed ID: 7536275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
    Evensen SA; Brinch L; Wisløff F
    Tidsskr Nor Laegeforen; 1989 Jun; 109(19-21):2004-6. PubMed ID: 2749689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
    Insiripong S; Thaisamakr S
    J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].
    Maeda N; Satake S; Okada Y; Asahara S; Hasuike N; Tamura M; Takata M; Tasaka K; Okutani T; Maeda Y; Tomofuji Y; Chinzei T; Saigo K
    Gan To Kagaku Ryoho; 2001 Mar; 28(3):407-10. PubMed ID: 11265415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
    Wakita A; Murase T; Uchida T; Fujiwara Y; Tanaka M; Ohkita T
    Gan To Kagaku Ryoho; 1992 May; 19(5):653-7. PubMed ID: 1580638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
    Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
    Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4467-73. PubMed ID: 17671131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Savani B
    Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and cytogenetic remission in a case of subtype M4E acute myelogenous leukemia with minimal monochemotherapy: high sensitivity or spontaneous remission?
    Martelli MP; Latagliata R; Spadea A; Avvisati G; Mancini M; Romano A; Luzi G; Petti MC
    Eur J Haematol; 2000 Sep; 65(3):203-6. PubMed ID: 11007057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.
    Vogler WR; McCarley DL; Stagg M; Bartolucci AA; Moore J; Martelo O; Omura GA
    Leukemia; 1994 Nov; 8(11):1847-53. PubMed ID: 7967730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
    Lobato-Mendizábal E; Ruiz-Argüelles GJ; Marín-López A
    Rev Invest Clin; 1989; 41(2):139-45. PubMed ID: 2675236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
    Wielenga JJ; Vellenga E; Groenewegen A; Sonneveld P; Löwenberg B
    Leukemia; 1996 Jan; 10(1):43-7. PubMed ID: 8558936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
    Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
    N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.